Type 2 diabetes, weight loss with dapagliflozin held until four years
Many patients with major type of weight loss diabetes after a year got more treatment dapagliflozin to metformin is weight loss with the drug for at least 4 years, regardless of whether they appear to maintain connected overweight or obese, the highlights of the analysis in the meeting with the American Diabetes company (ADA), which recently concluded in aspects of Boston.
It is good that the documented dapagliflozin, an antidiabetic agent belonging to the class of inhibitors, improved glycemic control cotransporter sodium-glucose type 2 (SGLT2), and reduced body weight in patients with type 2 diabetes studies have confirmed that weight loss in patients with overweight and obese people with type 2 diabetes is associated with an improved quality of life and glycemic control. In these subjects to weight loss, which are associated with other cardiovascular benefits.
To assess whether patients are overweight and obese with type 2 diabetes treated with dapagliflozin fails, new books lost at least four years for a program coordinated by Eva Johnsson, a researcher at AstraZeneca group conducted a post-hoc analysis a multicenter Phase III, controlled, randomized, double-blind part of the dapagliflozin development program.
In this study, the dell’SGLT2 inhibitor was compared to glipizide and the primary endpoint of the study was the effectiveness of glycemic control, as measured by changes in glycated hemoglobin from baseline after 52 weeks of treatment . This, however, post-hoc analysis evaluated researchers, body weight after 1, 2, 3 and 4 years.
All participants had type 2 diabetes, insufficiently controlled despite treatment with stable doses of metformin and randomization had HbA1c between 6.5% and 10%. patients were enrolled 406 assigned to the treatment (at a dose of ≤ 10 mg / day) and 408 to treatment with glipizide (a dose of ≤ 10 mg / day) dapagliflozin.
Most patients were white, and the men were a little “more than women. In addition, they were sick for about 6 years, the baseline BMI was equal to the level of HbA1c 31-32 and the line base was 7.7% in both treatment groups.
In the treatment arm of dapagliflozin, the average body weight loss was 3.55 kg after 12 months and the loss was maintained through week 208, while in the glipizide group in the first 2 years ago had a weight increase was that was reduced to 4 years.
The percentage of patients who achieved a weight loss after 4 years have treated more than 85% in the group with dapagliflozin and nearly 25% in the glipizide group, independent of BMI, Johnsson said.
Among patients treated with dapagliflozin demonstrated the weight lost after a year, 46.4% maintained at least 80% of the loss at 2 years, 34.8% maintained after 3 years and 30% after 1 four years taken.
The percentage of patients who achieved after a year at least 5% of their initial body weight by about 29% in the dapagliflozin group.this percentage gradually decreases weight loss up to 4 years, but is still significantly than the addition of the comparator treatment group.
The safety profiles were taken similar between the two treatment groups, with two exceptions, the researchers note. In fact, there were three major hypoglycemia in the glipizide group, while the group was confirmed in other genital infections dapagliflozin.
“Overall, we got a larger number of patients treated with dapagliflozin weight loss of up to 4 years, with a well-tolerated profile guaranteed,” said Johnsson.
“About a third of patients maintain weight loss in the first year was treated with dapagliflozin achieved in three and the proportion of those who have achieved and maintained weight loss in the group treated with the inhibitor dell’SGLT2 in obese subjects was similar, and those who are overweight, “concluded the researcher.